search
Back to results

N-Acetylcysteine in Patients With Sickle Cell Disease (NAC)

Primary Purpose

Sickle Cell Disease

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
N-Acetylcysteine
Placebo
Sponsored by
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Sickle Cell Disease focused on measuring Sickle Cell Disease, Sickle Cell Anemia, Pain, N-Acetylcysteine, Acetylcysteine, Oxidative stress

Eligibility Criteria

12 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 12 years or older
  • Sickle cell disease, either homozygous sickle cell disease (HbSS), compound heterozygous sickle cell disease (HbSC), HbSβ0 or HbSβ+ thalassemia
  • History of at least 1.0 painful crisis per year in the past 3 years (visit to medical facility is not required)

Exclusion Criteria:

  • Chronic blood transfusion or transfusion in the preceding 3 months
  • Painful crisis in the last 4 weeks (with respect to the moment of inclusion)
  • Pregnancy, breast feeding or the desire to get pregnant in the following 7 months
  • Known active gastric/duodenal ulcers
  • Hydroxycarbamide (HC) treatment with unstable dose in the last 3 months or started on HC shorter then 6 months prior to study
  • Known poor compliance in earlier trials regarding the completion of pain diaries
  • Insufficient compliance in run-in period
  • Known hypersensitivity to acetylcysteine or one of the other components of the study medication
  • Use of pain medication for sickle-cell related pains on more than 15 days per month in the past 6 months ('chronic pain').

Sites / Locations

  • CHU Brugmann
  • CHU St. Pierre
  • Hôpital Erasme
  • Hôpital Universitaire Des Enfants Reine Fabiola (HUDERF)
  • UCL St. Luc
  • CHR de la Citadelle
  • Academic Medical Center
  • University Medical Center Groningen
  • Erasmus Medical Center
  • Haga Hospital
  • Guys' & St. Thomas Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

N-Acetylcysteine

Placebo

Arm Description

N-Acetylcysteine 600mg 1 oral tablet twice daily during 6 months

Placebo 1 oral tablet twice daily during 6 months

Outcomes

Primary Outcome Measures

The incidence rate of SCD related pain in daily life per patient year
The incidence of pain in daily life will be expressed as the number of pain days in relation to total follow-up time, and transformed to an event rate per patient year with a corresponding rate ratio and its 95% confidence interval. A pain day will be defined as: When the box "Yes, I have experienced pain" is checked in the daily pain diary. Days with hospital admission for painful crisis will be included in the total number of pain days and in the total number of diary observation days, irrespective of pain diary reports on these dates.

Secondary Outcome Measures

The severity of SCD related pain in daily life, using a 0-10 numerical rating scale (NRS) in the study pain diary.
The average intensity of pain indicated on pain days in daily life will be compared between the two groups. The intensity of pain will be calculated as the average pain score over all pain days, using the highest scores indicated per day (either score over night or over day). Hospital days will be excluded from the analysis, as these scores often have not been completed fully during admission and the analysis is targeted at pain in daily life. Pain scores will be considered as continuous data with a normal distribution.
The incidence rate per patient year of painful crises (episodes, based on pain diary observation)
The number of patient-indicated painful crises in relation to total follow-up time will be transformed to an event rate per patient year, with a corresponding rate ratio and it's 95% confidence interval. Also, the average number of crisis days per patient in relation to total follow-up time will be evaluated (including hospital admission days, see below). A painful crisis will be defined as either (overlap is possible): When the box "Yes, I was in a crisis" is checked in a daily diary. Missing diary days that are immediately preceded and followed by crisis days or by hospital admission. A visit or admission to a hospital that lasted more than 4 hours for acute sickling-related pain, which was treated with orally or parenterally administered narcotics. An acute chest syndrome
The incidence rate per patient year of days with painful crises (days, based on pain diary observation)
The number of days with patient-indicated painful crises in relation to total follow-up time will be transformed to an event rate per patient year, with a corresponding rate ratio and it's 95% confidence interval. A painful crisis will be defined as either (overlap is possible): When the box "Yes, I was in a crisis" is checked in a daily diary. Missing diary days that are immediately preceded and followed by crisis days or by hospital admission. A visit or admission to a hospital that lasted more than 4 hours for acute sickling-related pain, which was treated with orally or parenterally administered narcotics. An acute chest syndrome
The severity of painful crises. This will be defined using a 0-10 numerical rating scale (NRS) in the pain diary.
The average intensity of pain indicated on crisis days in daily life will be compared between the two groups. The intensity of pain will be calculated as the average pain score over all crisis days, using the highest scores indicated per day (either score over night or over day). Hospital days will be excluded from the analysis, as these scores often have not been completed fully during admission and the analysis is targeted at pain in daily life. Pain scores will be considered as continuous data with a normal distribution. Painful crisis definition as above.
The incidence rate per patient year of hospital admissions
The number of sickle cell related hospital admissions in relation to total follow-up diary observation time will be transformed to an event rate per patient year, with a corresponding rate ratio and it's 95% confidence interval. Admissions will be verified using hospital medical records, if available. Hospital admission will be defined as: • Every visit to a hospital that lasted more than 4 hours for acute sickling-related disease, which was treated with orally or parenterally administered narcotics.
The incidence rate per patient year of hospital admission days
The number of sickle cell related hospital admission days in relation to total follow-up diary observation time will be transformed to an event rate per patient year, with a corresponding rate ratio and it's 95% confidence interval. Admissions will be verified using hospital medical records, if available. Hospital admission will be defined as: • Every visit to a hospital that lasted more than 4 hours for acute sickling-related disease, which was treated with orally or parenterally administered narcotics.
Time in days to first painful crisis (as defined above)
The time in days from randomization to first painful crisis (patient-defined) and hospital admission for painful crisis will be expressed in cumulative event rates, estimated by Kaplan-Meier analysis.
Time in days to first hospital admission for painful crisis (as defined above)
The time in days from randomization to first painful crisis (patient-defined) and hospital admission for painful crisis will be expressed in cumulative event rates, estimated by Kaplan-Meier analysis.
The health-related Quality of Life, as measured by use of validated questionnaires.
In adults this will be assessed with SF36-forms, a short-form health survey that has been proven to be valid and reliable in the black population.46 In children from 12 to 18 years old, we will use the PedsQL questionnaire, often used to assess quality of life in children, also validated in SCD patients
The SCD-related societal costs, assessed by a prospective cost-effectiveness analysis
The societal costs of pain care with the use of NAC, in the intervention group, will be compared to the societal costs of current pain care in the control group. Estimates of unit costs will be based on calculation of real costs of pain care. Generated direct medical costs will be recorded in the case record forms and by means of the Medical Cost Questionnaire (see appendix). Indirect costs arising from losses in productivity will be assessed by means of the Productivity Cost Questionnaire (see appendix) and will be calculated by means of the friction cost method.
The tolerability of NAC, defined as the number of participants with adverse events.
This will be assessed via the monthly adverse events reports. The frequency of registered adverse events and/or a serious adverse events will be reported per treatment arm, and compared between the two intervention groups.
The incidence rate per patient year of use of home pain medication (based on pain diary observation). This information will be recorded by subjects in their daily pain diary, including type and dosage of pain medication.
The incidence rate of analgesic usage will be defined as the proportion of pain days with reported analgesic use on the total number of pain days (excluding observation days with no reported pain). This proportion will be transformed to an event rate per patient year, with a corresponding rate ratio and it's 95% confidence interval.
Incidence of SCD complications.
The number of patients with sickle cell related complications (i.e. acute chest syndrome, stroke etc.) will be reported per treatment arm, and compared between the two intervention groups. The related incidence of SCD complications; Acute chest syndrome Priapism Hepatic sequestration Splenic sequestration Cerebrovascular accident Leg ulcer Symptomatic avascular osteonecrosis These complications will be assessed monthly by using hospital medical records.
The changes in blood markers of oxidative stress, hemolysis, hypercoagulability, inflammation, erythrocyte adhesion and endothelial dysfunction
Compliance of study medication; proportion of study medication used based on pill counts.
Compliance of use of study medication will primarily be checked by pill counts (number administered versus number returned). Compliance will be expressed as the proportion of tablets remaining, compared to the number of tablets that should have been taken based on a prescription of 2 tablets per day and the total number of observation days per patient.
Compliance of study medication; N-acetylcysteine plasma concentrations
We additionally aim to evaluate compliance by N-acetylcysteine plasma concentration measurements in blood samples drawn at T0, T3 and T6 in the intervention group, and assess mean change from baseline in the intervention group. This outcome may be used as alternative parameter for patient compliance if pill counts do not suffice.

Full Information

First Posted
May 6, 2013
Last Updated
June 30, 2016
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators
Erasmus Medical Center, Haga Hospital, University Medical Center Groningen, ZonMw: The Netherlands Organisation for Health Research and Development, Fonds NutsOhra, Stichting Janivo, CHU Brugmann, Brussels, Erasme University Hospital, Centre Hospitalier Régional de la Citadelle, University Hospital St Luc, Brussels, Centre Hospitalier Universitaire Saint Pierre, Queen Fabiola Children's University Hospital, Guy's and St Thomas' NHS Foundation Trust
search

1. Study Identification

Unique Protocol Identification Number
NCT01849016
Brief Title
N-Acetylcysteine in Patients With Sickle Cell Disease
Acronym
NAC
Official Title
N-Acetylcysteine in Patients With Sickle Cell Disease - Reducing the Incidence of Daily Life Pain
Study Type
Interventional

2. Study Status

Record Verification Date
June 2016
Overall Recruitment Status
Completed
Study Start Date
April 2013 (undefined)
Primary Completion Date
June 2016 (Actual)
Study Completion Date
June 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators
Erasmus Medical Center, Haga Hospital, University Medical Center Groningen, ZonMw: The Netherlands Organisation for Health Research and Development, Fonds NutsOhra, Stichting Janivo, CHU Brugmann, Brussels, Erasme University Hospital, Centre Hospitalier Régional de la Citadelle, University Hospital St Luc, Brussels, Centre Hospitalier Universitaire Saint Pierre, Queen Fabiola Children's University Hospital, Guy's and St Thomas' NHS Foundation Trust

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary aim of this study is to evaluate the effect of the drug N-Acetylcysteine on the frequency of pain in daily life in patients with Sickle Cell Disease (SCD). Pain is an invalidating hallmark of this disease and has a considerable impact on the Quality of Life of patients and the medical health care system. Oxidative stress is hypothesized to play a central role in its pathophysiology. In pilot studies the administration of N-Acetylcysteine (NAC) resulted in a reduction of oxidative stress. Moreover, administration of NAC seemed to decrease hospitalization for painful crises in a small pilot study in patients with SCD. This study will be performed as a multicenter, randomized, controlled trial where patients will be treated with either NAC or placebo for a period of 6 months. The investigators expect that NAC can reduce the frequency of pain in patients with SCD, thereby improving their quality of life and participation in society.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sickle Cell Disease
Keywords
Sickle Cell Disease, Sickle Cell Anemia, Pain, N-Acetylcysteine, Acetylcysteine, Oxidative stress

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
96 (Actual)

8. Arms, Groups, and Interventions

Arm Title
N-Acetylcysteine
Arm Type
Experimental
Arm Description
N-Acetylcysteine 600mg 1 oral tablet twice daily during 6 months
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo 1 oral tablet twice daily during 6 months
Intervention Type
Drug
Intervention Name(s)
N-Acetylcysteine
Other Intervention Name(s)
Acetylcysteine, Fluimicil, Acetadote
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
The incidence rate of SCD related pain in daily life per patient year
Description
The incidence of pain in daily life will be expressed as the number of pain days in relation to total follow-up time, and transformed to an event rate per patient year with a corresponding rate ratio and its 95% confidence interval. A pain day will be defined as: When the box "Yes, I have experienced pain" is checked in the daily pain diary. Days with hospital admission for painful crisis will be included in the total number of pain days and in the total number of diary observation days, irrespective of pain diary reports on these dates.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
The severity of SCD related pain in daily life, using a 0-10 numerical rating scale (NRS) in the study pain diary.
Description
The average intensity of pain indicated on pain days in daily life will be compared between the two groups. The intensity of pain will be calculated as the average pain score over all pain days, using the highest scores indicated per day (either score over night or over day). Hospital days will be excluded from the analysis, as these scores often have not been completed fully during admission and the analysis is targeted at pain in daily life. Pain scores will be considered as continuous data with a normal distribution.
Time Frame
6 months
Title
The incidence rate per patient year of painful crises (episodes, based on pain diary observation)
Description
The number of patient-indicated painful crises in relation to total follow-up time will be transformed to an event rate per patient year, with a corresponding rate ratio and it's 95% confidence interval. Also, the average number of crisis days per patient in relation to total follow-up time will be evaluated (including hospital admission days, see below). A painful crisis will be defined as either (overlap is possible): When the box "Yes, I was in a crisis" is checked in a daily diary. Missing diary days that are immediately preceded and followed by crisis days or by hospital admission. A visit or admission to a hospital that lasted more than 4 hours for acute sickling-related pain, which was treated with orally or parenterally administered narcotics. An acute chest syndrome
Time Frame
6 months
Title
The incidence rate per patient year of days with painful crises (days, based on pain diary observation)
Description
The number of days with patient-indicated painful crises in relation to total follow-up time will be transformed to an event rate per patient year, with a corresponding rate ratio and it's 95% confidence interval. A painful crisis will be defined as either (overlap is possible): When the box "Yes, I was in a crisis" is checked in a daily diary. Missing diary days that are immediately preceded and followed by crisis days or by hospital admission. A visit or admission to a hospital that lasted more than 4 hours for acute sickling-related pain, which was treated with orally or parenterally administered narcotics. An acute chest syndrome
Time Frame
6 months
Title
The severity of painful crises. This will be defined using a 0-10 numerical rating scale (NRS) in the pain diary.
Description
The average intensity of pain indicated on crisis days in daily life will be compared between the two groups. The intensity of pain will be calculated as the average pain score over all crisis days, using the highest scores indicated per day (either score over night or over day). Hospital days will be excluded from the analysis, as these scores often have not been completed fully during admission and the analysis is targeted at pain in daily life. Pain scores will be considered as continuous data with a normal distribution. Painful crisis definition as above.
Time Frame
6 months
Title
The incidence rate per patient year of hospital admissions
Description
The number of sickle cell related hospital admissions in relation to total follow-up diary observation time will be transformed to an event rate per patient year, with a corresponding rate ratio and it's 95% confidence interval. Admissions will be verified using hospital medical records, if available. Hospital admission will be defined as: • Every visit to a hospital that lasted more than 4 hours for acute sickling-related disease, which was treated with orally or parenterally administered narcotics.
Time Frame
6 months
Title
The incidence rate per patient year of hospital admission days
Description
The number of sickle cell related hospital admission days in relation to total follow-up diary observation time will be transformed to an event rate per patient year, with a corresponding rate ratio and it's 95% confidence interval. Admissions will be verified using hospital medical records, if available. Hospital admission will be defined as: • Every visit to a hospital that lasted more than 4 hours for acute sickling-related disease, which was treated with orally or parenterally administered narcotics.
Time Frame
6 months
Title
Time in days to first painful crisis (as defined above)
Description
The time in days from randomization to first painful crisis (patient-defined) and hospital admission for painful crisis will be expressed in cumulative event rates, estimated by Kaplan-Meier analysis.
Time Frame
6 months
Title
Time in days to first hospital admission for painful crisis (as defined above)
Description
The time in days from randomization to first painful crisis (patient-defined) and hospital admission for painful crisis will be expressed in cumulative event rates, estimated by Kaplan-Meier analysis.
Time Frame
6 months
Title
The health-related Quality of Life, as measured by use of validated questionnaires.
Description
In adults this will be assessed with SF36-forms, a short-form health survey that has been proven to be valid and reliable in the black population.46 In children from 12 to 18 years old, we will use the PedsQL questionnaire, often used to assess quality of life in children, also validated in SCD patients
Time Frame
6 months
Title
The SCD-related societal costs, assessed by a prospective cost-effectiveness analysis
Description
The societal costs of pain care with the use of NAC, in the intervention group, will be compared to the societal costs of current pain care in the control group. Estimates of unit costs will be based on calculation of real costs of pain care. Generated direct medical costs will be recorded in the case record forms and by means of the Medical Cost Questionnaire (see appendix). Indirect costs arising from losses in productivity will be assessed by means of the Productivity Cost Questionnaire (see appendix) and will be calculated by means of the friction cost method.
Time Frame
6 months
Title
The tolerability of NAC, defined as the number of participants with adverse events.
Description
This will be assessed via the monthly adverse events reports. The frequency of registered adverse events and/or a serious adverse events will be reported per treatment arm, and compared between the two intervention groups.
Time Frame
6 months
Title
The incidence rate per patient year of use of home pain medication (based on pain diary observation). This information will be recorded by subjects in their daily pain diary, including type and dosage of pain medication.
Description
The incidence rate of analgesic usage will be defined as the proportion of pain days with reported analgesic use on the total number of pain days (excluding observation days with no reported pain). This proportion will be transformed to an event rate per patient year, with a corresponding rate ratio and it's 95% confidence interval.
Time Frame
6 months
Title
Incidence of SCD complications.
Description
The number of patients with sickle cell related complications (i.e. acute chest syndrome, stroke etc.) will be reported per treatment arm, and compared between the two intervention groups. The related incidence of SCD complications; Acute chest syndrome Priapism Hepatic sequestration Splenic sequestration Cerebrovascular accident Leg ulcer Symptomatic avascular osteonecrosis These complications will be assessed monthly by using hospital medical records.
Time Frame
6 months
Title
The changes in blood markers of oxidative stress, hemolysis, hypercoagulability, inflammation, erythrocyte adhesion and endothelial dysfunction
Time Frame
6 months
Title
Compliance of study medication; proportion of study medication used based on pill counts.
Description
Compliance of use of study medication will primarily be checked by pill counts (number administered versus number returned). Compliance will be expressed as the proportion of tablets remaining, compared to the number of tablets that should have been taken based on a prescription of 2 tablets per day and the total number of observation days per patient.
Time Frame
6 months
Title
Compliance of study medication; N-acetylcysteine plasma concentrations
Description
We additionally aim to evaluate compliance by N-acetylcysteine plasma concentration measurements in blood samples drawn at T0, T3 and T6 in the intervention group, and assess mean change from baseline in the intervention group. This outcome may be used as alternative parameter for patient compliance if pill counts do not suffice.
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 12 years or older Sickle cell disease, either homozygous sickle cell disease (HbSS), compound heterozygous sickle cell disease (HbSC), HbSβ0 or HbSβ+ thalassemia History of at least 1.0 painful crisis per year in the past 3 years (visit to medical facility is not required) Exclusion Criteria: Chronic blood transfusion or transfusion in the preceding 3 months Painful crisis in the last 4 weeks (with respect to the moment of inclusion) Pregnancy, breast feeding or the desire to get pregnant in the following 7 months Known active gastric/duodenal ulcers Hydroxycarbamide (HC) treatment with unstable dose in the last 3 months or started on HC shorter then 6 months prior to study Known poor compliance in earlier trials regarding the completion of pain diaries Insufficient compliance in run-in period Known hypersensitivity to acetylcysteine or one of the other components of the study medication Use of pain medication for sickle-cell related pains on more than 15 days per month in the past 6 months ('chronic pain').
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bart Biemond, MD, PhD
Organizational Affiliation
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Karin Fijnvandraat, MD, PhD
Organizational Affiliation
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU Brugmann
City
Brussels
Country
Belgium
Facility Name
CHU St. Pierre
City
Brussels
Country
Belgium
Facility Name
Hôpital Erasme
City
Brussels
Country
Belgium
Facility Name
Hôpital Universitaire Des Enfants Reine Fabiola (HUDERF)
City
Brussels
Country
Belgium
Facility Name
UCL St. Luc
City
Brussels
Country
Belgium
Facility Name
CHR de la Citadelle
City
Liège
Country
Belgium
Facility Name
Academic Medical Center
City
Amsterdam
ZIP/Postal Code
1105 AZ
Country
Netherlands
Facility Name
University Medical Center Groningen
City
Groningen
ZIP/Postal Code
9713 GZ
Country
Netherlands
Facility Name
Erasmus Medical Center
City
Rotterdam
ZIP/Postal Code
3015 AA
Country
Netherlands
Facility Name
Haga Hospital
City
The Hague
ZIP/Postal Code
2545 CH
Country
Netherlands
Facility Name
Guys' & St. Thomas Hospital
City
London
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
18195334
Citation
Smith WR, Penberthy LT, Bovbjerg VE, McClish DK, Roberts JD, Dahman B, Aisiku IP, Levenson JL, Roseff SD. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008 Jan 15;148(2):94-101. doi: 10.7326/0003-4819-148-2-200801150-00004.
Results Reference
background
PubMed Identifier
20678158
Citation
Nur E, Brandjes DP, Schnog JJ, Otten HM, Fijnvandraat K, Schalkwijk CG, Biemond BJ; CURAMA Study Group. Plasma levels of advanced glycation end products are associated with haemolysis-related organ complications in sickle cell patients. Br J Haematol. 2010 Oct;151(1):62-9. doi: 10.1111/j.1365-2141.2010.08320.x. Epub 2010 Jul 30.
Results Reference
background
PubMed Identifier
21544855
Citation
Nur E, Biemond BJ, Otten HM, Brandjes DP, Schnog JJ; CURAMA Study Group. Oxidative stress in sickle cell disease; pathophysiology and potential implications for disease management. Am J Hematol. 2011 Jun;86(6):484-9. doi: 10.1002/ajh.22012. Epub 2011 May 4.
Results Reference
background
PubMed Identifier
21558001
Citation
Nur E, Verwijs M, de Waart DR, Schnog JJ, Otten HM, Brandjes DP, Biemond BJ, Elferink RP; CURAMA Study Group. Increased efflux of oxidized glutathione (GSSG) causes glutathione depletion and potentially diminishes antioxidant defense in sickle erythrocytes. Biochim Biophys Acta. 2011 Nov;1812(11):1412-7. doi: 10.1016/j.bbadis.2011.04.011. Epub 2011 May 3.
Results Reference
background
PubMed Identifier
22318468
Citation
Nur E, Brandjes DP, Teerlink T, Otten HM, Oude Elferink RP, Muskiet F, Evers LM, ten Cate H, Biemond BJ, Duits AJ, Schnog JJ; CURAMA study group. N-acetylcysteine reduces oxidative stress in sickle cell patients. Ann Hematol. 2012 Jul;91(7):1097-105. doi: 10.1007/s00277-011-1404-z. Epub 2012 Feb 10.
Results Reference
background
PubMed Identifier
12701116
Citation
Pace BS, Shartava A, Pack-Mabien A, Mulekar M, Ardia A, Goodman SR. Effects of N-acetylcysteine on dense cell formation in sickle cell disease. Am J Hematol. 2003 May;73(1):26-32. doi: 10.1002/ajh.10321.
Results Reference
background
PubMed Identifier
15606557
Citation
Somjee SS, Warrier RP, Thomson JL, Ory-Ascani J, Hempe JM. Advanced glycation end-products in sickle cell anaemia. Br J Haematol. 2005 Jan;128(1):112-8. doi: 10.1111/j.1365-2141.2004.05274.x.
Results Reference
background
PubMed Identifier
20575034
Citation
van Tuijn CF, van Beers EJ, Schnog JJ, Biemond BJ. Pain rate and social circumstances rather than cumulative organ damage determine the quality of life in adults with sickle cell disease. Am J Hematol. 2010 Jul;85(7):532-5. doi: 10.1002/ajh.21731. No abstract available.
Results Reference
background
Available IPD and Supporting Information:
Available IPD/Information Type
Statistical Analysis Plan
Available IPD/Information URL
http://www2.hematologie-amc.nl/nac_studie
Available IPD/Information Identifier
Version 7.0 - 5/31/2016

Learn more about this trial

N-Acetylcysteine in Patients With Sickle Cell Disease

We'll reach out to this number within 24 hrs